AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9844762
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CSA) at a dosage of 3 mg/kg/day
Trial: 9844762
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) at a dosage of 0.15 mg/kg/week
Trial: 8029807
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day aspirin for seven days
Trial: 8029807
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day aspirin for seven days
Trial: 8029807
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day aspirin for seven days
Trial: 8029807
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg aspirin/day for one week
Trial: 8029807
Drug: 600 or
RxNorm normalized name: MST 600 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 or 1200 mg aspirin (single dose)
Trial: 1079063
Drug: 25 percent
RxNorm normalized name: METHYL SALICYLATE 250 mg in 1 mL TOPICAL CREAM [Methyl Salicylate 25 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 percent component therapy (Group 3)
Trial: 1079063
Drug: Component therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Component therapy
Trial: 26468956
Drug: Twice-per-day dosing
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-per-day dosing regimen
Trial: 16215339
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg preoperatively
Trial: 3010707
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and hydrochlorothiazide combination therapy
Trial: 22912445
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of colistine sulfate/kg of diet (antibiotic)
Trial: 17324008
Drug: ISA 247
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA 247 (0.2 mg/kg bid)
Trial: 17324008
Drug: ISA 247
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA 247 (0.3 mg/kg bid)
Trial: 17324008
Drug: ISA 247
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA 247 (0.4 mg/kg bid)
Trial: 17324008
Drug: ISA 247
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA 247 (mid dose)
Trial: 11773574
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (200,000 IU, half that dose if <12 months)
Trial: 2800986
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg/kg plus N2O/O2 (Group P, reference group)
Trial: 50014
Drug: Facilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitation treatment approach
Trial: 50014
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment approach
Trial: 30932317
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 2.5 × 10^9 CFUs, once daily)
Trial: 30624674
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs) containing 20 mg Fe/d until 6 mo postpartum, and SQ-LNSs for infants from 6 to 18 mo of age (LNS)
Trial: 30624674
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs)
Trial: 30624674
Drug: Iron (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (60 mg/d) and folic acid (IFA)
Trial: 30624674
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (MMN) containing 20 mg Fe/d until 6 mo postpartum
Trial: 9590467
Drug: Brompheniramine 12
RxNorm normalized name: BROMPHENIRAMINE 12MG/PSEUDOEPHEDRINE 120MG CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompheniramine 12 mg twice daily
Trial: 3398891
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus interferon (2 X 10(6) IU per square meter of body-surface area, daily for one week, then three times per week for one year)
Trial: 28873709
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup (8.74g of FOS/day)
Trial: 28873709
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup incorporated in yogurt
Trial: 22964266
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy (MBT-AS)
Trial: 20171048
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg/kg
Trial: 20171048
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 10 mg/kg
Trial: 20171048
Drug: Combined autologous
RxNorm normalized name: chondrocytes, autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined autologous and allogenic transfusion (Treatment groups)
Trial: 18369313
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DVS
Trial: 18369313
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DVS
Trial: 18369313
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg DVS
Trial: 18369313
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DVS
Trial: 17235475
Drug: Combination preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination preparation (cinnarizine 20 mg and dimenhydrinate 40 mg)
Trial: 17235475
Drug: Betahistine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (12 mg betahistinedimesilate)
Trial: 10831147
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 500 microg daily via dry powder inhalation (Rotadisk)
Trial: 16391172
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg clonidine
Trial: 16391172
Drug: 0.1‐mg/h nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mg/h nitroglycerin transdermal patch
Trial: 14597946
Drug: Lisinopril (uptitrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (uptitrated to 20 mg/d)
Trial: 14597946
Drug: Valsartan (uptitrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (uptitrated to 160 mg/d)
Trial: 10759621
Drug: Extra strength
RxNorm normalized name: APAP Extra Strength
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra strength antacids
Trial: 8752254
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium plus oral clodronate, 400 mg/day
Trial: 8752254
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium plus oral clodronate, 400 mg/day for 30 days, followed by 60 days of calcium supplement alone (cyclical regimen)
Trial: 8752254
Drug: Oral calcium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral calcium, 1000 mg/day (control)
Trial: 8752254
Drug: Continuous clodronate
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous clodronate treatment
Trial: 8752254
Drug: Cyclical clodronate
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical clodronate treatment
Trial: 31668477
Drug: D1 agonist
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist (PF-06412562) 6 mg
Trial: 31668477
Drug: D1 agonist
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist (PF-06412562) 15 mg
Trial: 31668477
Drug: D1 agonist
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist (PF-06412562) 30 mg
Trial: 31668477
Drug: D1 agonist
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist (PF-06412562) 6 mg, 15 mg, 30 mg
Trial: 27288381
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen at a dose of 800 mg three times daily
Trial: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (RSV) 10 mg/d
Trial: 22573476
Drug: Rosuvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin plus Ezetimibe (RSV/EZT) 10 mg/d
Trial: 20552577
Drug: Luteinizing-hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing-hormone-releasing hormone (LHRH) agonists for ovarian function suppression (OFS)
Trial: 19399720
Drug: LHRH agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonists
Trial: 18156478
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous 2% lignocaine eardrops
Trial: 6401551
Drug: Slow sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow sodium tablets
Trial: 14513587
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy combined with ultrasonic subgingival scaling and root planning (SRP)
Trial: 8967666
Drug: 1.4 mg
RxNorm normalized name: phenol 1.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 mg of rhGH once daily plus placebo twice daily
Trial: 8967666
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of rhIGF‐1 twice daily plus placebo once daily
Trial: 8967666
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of rhIGF‐1 twice daily plus 1.4 mg of rhGH once daily
Trial: 6275871
Drug: Neostigmine 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypercarbia group
Trial: 6275871
Drug: Neostigmine 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypocarbia group
Trial: 6275871
Drug: Neostigmine 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in normocarbia group
Trial: 19884558
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT)
Trial: 26940892
Drug: Zolpidem or
RxNorm normalized name: zolpidem Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem or Trazodone (second stage therapy)
Trial: 26940892
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) or Cognitive therapy (CT) (second stage therapy)
Trial: 26940892
Drug: Sleep parameters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep parameters from daily sleep diaries and polysomnography
Trial: 26940892
Drug: Adverse events,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse events, dropout rates, treatment acceptability
Trial: 24630938
Drug: L/L genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/L genotype
Trial: 22089461
Drug: Civamide cream
RxNorm normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Civamide cream 0.075%
Trial: 22089461
Drug: Civamide cream
RxNorm normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Civamide cream 0.01% (control)
Trial: 11988188
Drug: Oral nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nitroglycerin 400 microg
Trial: 7702049
Drug: r‐HuEPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO treatment
Trial: 45602
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine at 600 CCA
Trial: 45602
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine at 200 CCA
Trial: 45602
Drug: Whole-virus vaccine
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccine at 200 CCA
Trial: 25377429
Drug: Pregabalin 5
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 5 mg/kg/day
Trial: 25377429
Drug: Pregabalin 10
RxNorm normalized name: pregabalin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 10 mg/kg/day
Trial: 18379519
Drug: Local injections
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injections of tolperisone (midocalm) combined with tractional therapy, 3-6 injections
Trial: 18379519
Drug: Tractional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tractional therapy without midocalm (placebo)
Trial: 16116148
Drug: Peer-counseling program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-counseling program with up to six telephone calls from a trained childhood cancer survivor, tailored materials, and free nicotine replacement therapy
Trial: 16080909
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (Viagra) 100 mg
Trial: 9500298
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol and salmeterol
Trial: 16575035
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg iv
Trial: 4605245
Drug: Dummy injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy injection (Control)
Trial: 24139323
Drug: Strongest Families
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strongest Families Smart Website intervention with weekly telephone coaching sessions
Trial: 18326055
Drug: Kinematic outcome
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinematic outcome measures (e.g., peak hand velocity, endpoint error, reach extent, maximum shoulder flexion range of motion, minimum elbow extension range of motion)
Trial: 6355314
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg, 10-day course, four times daily)
Trial: 6355314
Drug: Rosaramicin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosaramicin (250 mg, 10-day course, four times daily)
Trial: 30395052
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg)
Trial: 27079848
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose IgG (M = 794.93; SD = 90.48)
Trial: 27079848
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose IgG (M = 283.89; SD = 71.10)
Trial: 24791643
Drug: Imagery Relief
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery Relief Therapy (IRT)
Trial: 17967668
Drug: Lidocaine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (0.5 mg/kg)
Trial: 19560905
Drug: Procaine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine (0.5 mg/kg and 1.0 mg/kg)
Trial: 18044436
Drug: Vaccination (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination (three doses at 3-week intervals)
Trial: 2097484
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine in 2 ml saline
Trial: 2097484
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine in 10 ml saline
Trial: 2097484
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine in 20 ml saline
Trial: 7027745
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of verapamil during standardized oral glucose load
Trial: 7027745
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil treatment after one week during standardized oral glucose load
Trial: 7027745
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo during standardized oral glucose load
Trial: 17209192
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg gluten
Trial: 22357413
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg for 12 weeks
Trial: 22357413
Drug: Perindopril 10
RxNorm normalized name: amlodipine-perindopril 10 mg-14 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 10 mg for 12 weeks
Trial: 17581448
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (MPH-IR) at doses of 0.1, 0.3, and 0.5 mg/kg twice daily for 2 weeks.
Trial: 11756063
Drug: Sterol ester-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterol ester-1 (2.3 g plant sterol esters)
Trial: 11756063
Drug: Stanol ester-1
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanol ester-1 (2.5 g plant stanol esters)
Trial: 8267679
Drug: Bromfenac 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 50 mg
Trial: 7937271
Drug: Bromfenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 100 mg
Trial: 9690243
Drug: Bromfenac 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 200 mg
Trial: 8106772
Drug: Pyrimethamine, 25
RxNorm normalized name: Pyrimethamine, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine, 25 mg thrice weekly
Trial: 2669218
Drug: Prednisolone only
RxNorm normalized name: Prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone only series (60 mg daily for one month, then reduced to 20 mg on alternate days)
Trial: 2669218
Drug: Cyclophosphamide-prednisolone series
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide-prednisolone series (100-120 mg cyclophosphamide daily plus 20 mg prednisolone on alternate days)
Trial: 2669218
Drug: Death or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Death or failure of first treatment regimen
Trial: 58317
Drug: Sampling cervix
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sampling cervix twice
Trial: 31520538
Drug: Bite splint
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bite splint therapy
Trial: 28074796
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser therapy (660 NM, spatial average energy fluency of 1.06 J/cm2)
Trial: 19492956
Drug: 1-day application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day application of topical 0.5% moxifloxacin, 4 times a day for 1 day, n = 63
Trial: 15050762
Drug: ETT palpation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETT palpation and adjustment (Treatment)
Trial: 17767063
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy group (diet control combined with aerobic exercises)
Trial: 10394257
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of bisoprolol
Trial: 10394257
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of verapamil LP
Trial: 8893576
Drug: FUT‐175 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT‐175 (10 mg/L) during CPB
Trial: 6350625
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg. per kg. intramuscularly every 8 hours)
Trial: 23666554
Drug: Benzylpiperazine (BZP)
RxNorm normalized name: cinnamido benzylpiperidinyl ethoxypropylbenzamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpiperazine (BZP) 200 mg